Ligand Pharmaceuticals (LGND) Peer Comparison
$289.50
As on 20-Nov-2026 12:39EST
Market cap
$6,177 Mln
Revenue (TTM)
$254 Mln
P/E Ratio
124
P/B Ratio
6.6
Div. Yield
0 %
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
6,177 | 15,253 | 13,385 | 12,313 | 7,983 |
Revenue ($ Mln) |
254 | 946 | 5,148 | 331,377 | 964 |
Net Profit ($ Mln) |
51.46 | -570.21 | -147.00 | 28,032.40 | 162.01 |
Net Margin (%) |
20.27 | -60.30 | -2.86 | 8.46 | 16.81 |
RoE (%) |
5.25 | -- | -2.24 | 7.51 | 22.02 |
Price to Earnings |
124.01 | -- | -- | 41.03 | 54.84 |
Price-To-Book |
6.58 | 123.68 | 2.00 | 2.99 | 9.46 |
Income Statement ($ Mln)
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
253.83 | 945.54 | 5,148.00 | 331,377.21 | 963.65 |
|
Cost of Revenue
|
-18.05 | 61.34 | 2,395.00 | 167,448.74 | 14.10 |
|
Gross Profit
|
261.50 | 473.81 | 2,050.00 | 190,428.00 | 748.43 |
|
Operating Expenses
|
241.64 | 1,294.12 | 2,237.00 | 134,367.32 | 838.64 |
|
Operating Profit (EBIT)
|
30.24 | -409.91 | 516.00 | 29,561.14 | 110.91 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
52.73 | -578.95 | -92.00 | 35,270.62 | 131.43 |
|
Provision for Tax
|
1.27 | -4.96 | 55.00 | 7,639.53 | -37.31 |
|
Profit after Tax (Net Income)
|
51.46 | -570.21 | -147.00 | 28,032.40 | 162.01 |
|
Minority Interest
|
0.00 | 11.75 | 0.00 | 401.00 | 0.00 |
|
Consolidated Profit
|
0.00 | 0.00 | 0.00 | 12,099.00 | 0.00 |
Liabilities ($ Mln)
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
961.76 | -1,662.34 | 6,628.00 | 387,871.57 | 833.74 |
|
Minority Interest
|
0.00 | 11.75 | 0.00 | 401.00 | 0.00 |
|
Non-Current Liabilities
|
775.13 | 2,838.05 | 4,925.00 | 30,754.20 | 22.61 |
|
Current Liabilities
|
500.57 | 977.24 | 1,787.00 | 155,168.12 | 177.68 |
|
Total Liabilities
|
1,560.64 | 936.03 | 13,358.00 | 492,989.00 | 836.65 |
Assets ($ Mln)
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
1,629.23 | 117.18 | 9,614.00 | 278,119.64 | 500.15 |
|
Current Assets
|
608.23 | 2,044.61 | 3,726.00 | 298,879.23 | 533.87 |
|
Total Assets
|
1,560.64 | 936.03 | 13,358.00 | 492,989.00 | 836.65 |
|
Total Debt*
|
1,154.21 | 2,494.05 | 3,707.00 | 72,603.83 | 8.99 |
|
Net Current Assets
|
107.67 | 1,067.37 | 1,939.00 | 143,084.00 | 356.20 |
Cashflow ($ Mln)
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
49.36 | -445.91 | 560.00 | 46,428.00 | 142.00 |
|
Cash Flow from Investing Activities
|
-377.32 | -24.49 | -279.00 | -58,077.00 | 69.76 |
|
Cash from Financing Activities
|
428.22 | 359.29 | -275.00 | 18,911.00 | -220.37 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
10.79 | -159.44 | -2.21 | 16.61 | 14.87 |
|
ROE (%)
|
5.25 | 41.15 | -2.24 | 7.51 | 22.02 |
|
ROA (%)
|
2.42 | -26.19 | -0.98 | 3.93 | 14.68 |
|
EBIT Margin (%)
|
22.60 | -47.10 | 3.15 | 9.79 | 13.64 |
|
Net Margin (%)
|
20.27 | -60.30 | -2.86 | 8.46 | 16.81 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
1.03 | 167.27 | 12.13 | -3.15 | 30.02 |
|
EBIT Growth (%)
|
-12.91 | 34.77 | -26.70 | -59.13 | 48.49 |
|
Net Profit Growth (%)
|
5.93 | 28.47 | -508.33 | -52.18 | 53.19 |
|
EPS Growth (%)
|
7.91 | 30.63 | -519.61 | -52.16 | 45.73 |
|
Book Value Growth (%)
|
4.60 | 16.42 | -3.67 | 8.16 | 27.91 |
Valuation Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
32.11 | -20.69 | -48.47 | 0.19 | 41.86 |
|
Price / Book Value
|
3.93 | -7.27 | 1.72 | 0.03 | 6.44 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
19.27 | -25.47 | 21.77 | 0.00 | 55.67 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.71 | -1.16 | 0.55 | 0.03 | 0.00 |
|
Short term debt to equity ratio
|
0.47 | -0.33 | 0.01 | 0.16 | 0.00 |
|
Current Ratio
|
1.22 | 2.09 | 2.09 | 1.93 | 3.00 |
|
Quick Ratio
|
1.19 | 2.03 | 1.07 | 1.40 | 2.94 |
|
Interest Coverage
|
7.45 | -3.33 | 0.65 | 8.78 | -- |
Operating Efficiency Ratios
| Ligand Pharmaceuticals (LGND) | BridgeBio Pharma (BBIO) | Elanco Animal Health (ELAN) | Dr. Reddy's Laboratories - ADR | Corcept Therapeutics (CORT) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
42.36 | 39.67 | 20.65 | 30.73 | 11.53 |
|
Asset Turnover
|
0.12 | 0.43 | 0.34 | 0.46 | 0.87 |
|
Receivable days
|
70.50 | 52.44 | 70.73 | 115.08 | 28.27 |
|
Inventory Days
|
644.28 | 172.81 | 226.89 | 181.99 | 355.76 |
|
Payable days
|
234.84 | 296.14 | 45.50 | 56.23 | 785.55 |
|
Cash Conversion Cycle
|
479.94 | -70.89 | 252.12 | 240.84 | -401.52 |